|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.09.25 - 23:51
|
XETR: NEW INSTRUMENT AVAILABLE - 05.09.2025 - US75886F1075 (XETRA)
|
|
|
Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY hat seinen ersten Handelstag am 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y
The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its first trading date on 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y...
|
|
|
|
|
|
|
02.09.25 - 14:06
|
Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector (Business Wire)
|
|
|
Not intended for UK-based mediaDARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector.
Weinreich is a highly-regarded biopharma leader with extensive experience and a proven track record in R&D. He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career. In addition, Weinreich has founded multiple companies and served as a venture capitalist, board member, and biotech CEO. Weinreich joins Merck KGaA, Darmstadt, Germany from Foresite Labs & Foresite Capital Management LLC, where he served as an Operating Partner and Senior Advisor. His previous experience includes: Executive Vice President, Head, Global Clinical Development at Regeneron; Corporate Senior Vice President, Head, Global Development Specialty Medicine at Bayer; and Execu...
|
|
|
02.09.25 - 14:06
|
Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector (Business Wire)
|
|
|
Not intended for Canada-, UK- or US-based mediaDARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector.
Weinreich is a highly-regarded biopharma leader with extensive experience and a proven track record in R&D. He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career. In addition, Weinreich has founded multiple companies and served as a venture capitalist, board member, and biotech CEO. Weinreich joins Merck from Foresite Labs & Foresite Capital Management LLC, where he served as an Operating Partner and Senior Advisor. His previous experience includes: Executive Vice President, Head, Global Clinical Development at Regeneron; Corporate Senior Vice President, Head, Global Development Specialty Medicine at Bayer; and Executive Medical Director, Global Prod...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
